Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : The Trump Presidency -- Ignore unavailable to you. Want to Upgrade?

To: i-node who wrote (192769)	1/30/2021 8:08:37 PM
From: J_F_Shepard	1 Recommendation Recommended By CentralParkRanger Respond to of 361444

The "If" is that it must be administered correctly and within a day or two of contracting the virus. You cannot wait on test results. High risk individuals must start the protocol immediately on diagnosis based on symptoms. And is based on clinical studies? Published where?? We know why it works. Do we.....? Do you? There are innumerable studies which show without any question that HCQ + ZPak + Zinc + Vit D and various other combinations, cures COVID. Post just one of those studies, not anecdotal bull shit.. You're losing it Nodey...

To: i-node who wrote (192769)	1/30/2021 8:23:25 PM
From: J_F_Shepard	Read Replies (2) \| Respond to of 361444

Epidemiologist Harvey Risch, at Yale, has complied a large number of studies proving it works. YSPH professor criticized for promoting unproven drug to treat COVID-19 Charlotte Zimmer 5:33 pm, Aug 16, 2020 Staff Reporter Yale School of Public Health professor Harvey Risch has been a vocal supporter of the use of hydroxychloroquine to treat COVID-19, despite a lack of scientific evidence that it works. In a July 23 opinion piece in Newsweek, Risch argued for the use of hydroxychloroquine, in combination with the antibiotic azithromycin, to treat high-risk COVID-19 patients without waiting for further testing on the effectiveness of the treatment. He published this piece after his May 27 paper in the American Journal of Epidemiology was widely criticized due to a lack of evidence from randomized trials. Both articles argued this combination of drugs can effectively prevent hospitalization for most symptomatic high-risk outpatients and that it is safe for short-term use early in the course of infection. This claim is now widely disputed.